Institute for Clinical and Economic Review Issues Final Report and Policy Recommendations on Acute Treatments for Migraine
February 26, 2020
February 26, 2020
BOSTON, Massachusetts, Feb. 26 -- The Institute for Clinical and Economic Review issued the following announcement:
The Institute for Clinical and Economic Review (ICER) released a Final Evidence Report and Report-at-a-Glance assessing the comparative clinical effectiveness and economic value of three acute treatments for migraine: lasmiditan (Reyvow(TM), Eli Lilly), rimegepant (Biohaven), and ubrogepant (Ubrelvy(TM), Allergan). ICER's report on these therapies was reviewed at . . .
The Institute for Clinical and Economic Review (ICER) released a Final Evidence Report and Report-at-a-Glance assessing the comparative clinical effectiveness and economic value of three acute treatments for migraine: lasmiditan (Reyvow(TM), Eli Lilly), rimegepant (Biohaven), and ubrogepant (Ubrelvy(TM), Allergan). ICER's report on these therapies was reviewed at . . .